See SmartLabs in Action!

See SmartLabs in Action!

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors

- Advances in oRNA expression and delivery enable pipeline of therapeutics across a diverse range of disease areas

- Lead is CAR program shows possibility of tumor eradication in preclinical animal models with promise of translation to non-human primates and patients

The FOYA judging committee commends CRISPR for creating a flexible, digitally-enabled facility that can bring the promise of innovation to life.

- Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers

- Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency of CUE-100 series platform

Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced an update to its strategic priorities to focus on developing SGT-001 and SGT-003. The company also announced financial results for the first quarter ended March 31, 2022.

Following a management shake-up, Editas Medicine received some welcome good news. The biotech has scored a second rare pediatric disease designation from the FDA for its gene edited medicine EDIT-301.

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the entire cell and gene therapy community from Europe and beyond.

Learn More About How Are We Building Labs That Today's Science Deserves 

Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform.